CXCL9 and neoplasm: In another study, ginseng-derived EVs reprogram tumor-associated macrophages (TAMs), increasing the secretion of CCL5 and CXCL9 to recruit CD8+ T cells into the tumor core, thereby enhancing the efficacy of immune checkpoint blockade therapy with PD-1 monoclonal antibodies (Han et al., 2022).